+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anti Tumour Necrosis Factor"

REMICADE Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

REMICADE Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
HUMIRA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

HUMIRA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
CIMZIA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CIMZIA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
ENTYVIO Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ENTYVIO Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
From
From
From
From
From
From
From
Anti-Inflammatory Therapeutics Market 2024-2028 - Product Thumbnail Image

Anti-Inflammatory Therapeutics Market 2024-2028

  • Report
  • May 2024
  • 174 Pages
  • Global
From
From
From
From
From
Ulcerative Colitis Epidemiology Analysis and Forecast, 2021-2031 - Product Thumbnail Image

Ulcerative Colitis Epidemiology Analysis and Forecast, 2021-2031

  • Report
  • February 2023
  • 48 Pages
  • Global
From
Loading Indicator

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications. The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more